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Is it ethical in this setting to conduct a placebo-controlled trial when a drug that is known to prolong survival exists? Is it acceptable to design a clinical study to answer an economic auestion?
In the U.S., RCTs are conducted to determine if a drug is effective for the treatment of a given condition; evidence provided by such trials is instrumental in winning FDA approval for marketing of the drug. Therefore, in a sense, the point of an RCT is to determine whether a drug should be made available to the public. The case a t hand is a variation on this theme. It is of no real benefit to people with AIDS in a poor, developing society to be told that there is a drug for their condition, but that it is out of their reach because of resource constraints. Results of the proposed RCT will determine whether ddC will be made available to the public.
The mere existence of a n expensive or of a relatively cost-ineffective drug elsewhere constitutes only theoretical availability to patients in the developing world. The very need to conduct research such as the present case illustrates the point that a drug shown to be effective in the developed world meets only the first s t a n d a r d t h a t determines availability in the developing world, where drugs must also meet the standards of affordability, and, more precisely, cost effectiveness. The latter refers to the net cost required to obtain a gven benefit from medical care. Cost-effectiveness analyses must be undertaken from a specific perspective, usually that of the patient, the health care provider, a private third-party payor, or a government. Such an analysis is distinct from cost-benefit analysis in that no assessment of whether the cost is "worth" the benefit is made.2
Questions of medical economics, such as those of cost effectiveness or resource allocation, are of critical importance in much of the developJuly-August 1991 ing countries, bioethical decisionmaking is potentially powerfully c o n s t r a i n e d by t h e fact t h a t healthcare resources are often severely limited.3 Cost alone is frequently a n important factor in determining which drugs many countries place on their formularies.* In most South American countries, the vast majority of patients cannot pay for AIDS drugs with their own funds. Moreover, private insurers in South America typically specifically exclude from coverage infectious diseases of all types, including AIDS; hence zidovudine is presently not covered. The national governments therefore bear the financial burden for such medication. The proposed ddCplacebo trial thus promises to provide crucial information that the government needs in determining how to spend its scarce health care funds. Indeed, data provided by the trial will determine which drug, if any, the government elects to make available to its people.
Hence, comparison of ddC to placebo is not unethical if the cost of zidovudine i s beyond what the government could possibly afford. If zidovudine is known to be too expensive -or too cost ineffective -for a given society to purchase at all, for the purposes of the ethical design of a research s t u d y it i s a s if zidovudine did not exist. It is possible, in other words, that the government of a developing country may decide t h a t antiretroviral therapy of one type or another (e.g., ddC, zidovudine, etc.) is not more cost effective than simple supportive care. This is a legitmate concern in a setting of scarce r e s o~r c e s .~ We recognize that this stance invites possible discrimination by the government against certain classes of patients. Certainly cost effectiveness alone is not the only way a government formulary should be developed. Other considerations, such as equity, disease severity, and disease prevalence, are also important. Our point here is simply that cost and cost effectiveness are clearly legitimate concerns and-sadly in the developing world-must sometimes be prospectively evaluated. Indeed, from the perspective of a developing society, it is hard to justify huge expenditures on drugs for a given condition when there are other, more readily treatable conditions for which affordable and costeffective therapy is available.
Simple cost finding alone, however, may be misleading. This was the case for zidovudine treatment for patients with asymptomatic HIV infection in the United States. Although there was an initial outcry in the popular press about the "unfair" high price of zidovudine, health economists have shown t h a t zidovudine therapy is actually more cost effective in terms of cost per year of life gained t h a n many therapies commonly provided in the developed world, such as treatment for high blood cholesterol or screening mamrn~graphy.~ To jusbfy the use of ddC as the study drug in this developing world study, two criteria must thus be met. One is that there must be some expectation that ddC will be clinically effective. This has been met in the present case. Indeed, a number of phase I trials have been completed and phase I1 trials are under way in the developed world (all of which compare ddC to zidovudine or provide alternating doses of ddC and zidovudine). The other criterion is that sufficient pricing data must be available prior to the outset of the study to permit the expectation that ddC would indeed be more cost effective than zidovudine. That is, there must be honest reason to believe that ddC might be more cost effective when compared to placebo and more cost effective than zidovudine. Insufficient data have been provided in this case to determine whether this second expectation has been met.
In the present case, the RCT is specifically designed to control for cost effectiveness of antiretroviral therapy by having a placebo group. This feature of the study design is necessitated by the goal of answering an economic question. Provided this does not come at the expense of harming patients, we believe this is acceptable. In other words, it is essential that in studies such as the present case, there be no a priori reason to expect that ddC will be worse for patients, clinically speaking, than placebo (indeed, there should be some reason to expect that it will be better than or at least equivalent to placebo). Patients should not knowingly be harmed. Moreover, if we accept the premise that an RCT to answer an economic question is necessary and appropriate, then we must permit the study to be designed in a way that affords an answer to the question. It would clearly be unethical to subject research subjects to risk at all if the study were poorly d e~i g n e d .~ Trials evaluating the efficacy of ddC in the United States would ordinarily not include a placebo arm. Zidovudine h a s been shown to prolong survival of patients with AIDS or ARC and to delay the onset of AIDS or ARC in certain patients with asymptomatic HIV infection. Because zidovudine is presently available to all patients in the United States for whom it is indicated, a trial of a new antiretroviral agent that would deny the opportunity for the survival advantage of zidovudine over placebo is ~n e t h i c a l .~ In developing nations that do not, because of expense, provide zidovudine to any patients, however, a trial designed to evaluate ddC against placebo is not unethical. There are two final ethical expectations that we believe must be met in conducting this study. First, the study should receive the approval of a local body that reviews the ethical design of clinical research. One problem with this type of trial is that it sets the stage for possible abuse of developing world citizens in research studies. This is clearly unacceptable. It is hoped that local review might mitigate this possibility. Second, a contingency of this trial must be a prior cornrnitment by the drug manufacturer and the sponsoring government to provide ddC to the population should it prove to be clinically active and cost effe~tive.~ This case serves to illustrate the increasing complexity of bioethical decisionmaking as cultural barriers are breached by a n expanding Western medicine. Despite the appeal a n d prominence of nonWestern medical systems, Western biomedicine has become the only truly cosmopolitan system of medicine. This has found several expressions, including the increased movement of Western researchers into non-Western settings and the increased role played by international pharmaceutical concerns.lo Ethical decisionmaking in non-Western settings and the existence of disparate ethical standards are appropriately receiving increasing attention as medical research becomes more international.
Ethical rules are fashioned by a particular group within a particular cultural tradition and under particular environmental and economic constraints. The ethical expectations regarding research with human subjects may therefore be expected to vary from society tosociety. Not surprisingly, there is defensible variability in ethical norms. We believe that certain repatientswith human imm-ciq d d c : International interests in AIDS -0i n f i n-ofw control. h u m a n immunodeficiency virus issues become relevant to whether berg J:Clinicalecommics:Aguide to the ( H m .' They question whether it is the trial is ethical. In particular, economic analysis of cliriacalpractices.
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